All In Biotech

Drug Trial Radar · NCT04970654

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

A Trial Comparing the Efficacy and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Chinese Children With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Jul 22, 2021

Primary completion

Nov 17, 2023

Study completion Dec 18, 2023

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study compares two medicines for children with a low level of hormone to grow: somapacitan (a new medicine) given once a week and Norditropin® (a medicine doctors can already prescribe) given once a day. Researchers will test somapacitan to see how well it works, compared to the standard treatment with Norditropin®. The participants will either get Norditropin® once every day or somapacitan once every week - which treatment the participant gets is decided by chance. The participant and the study doctor will know which treatment the participant gets. The study includes a 52 week treatment period and a minimum of 30 days follow up period.

Conditions

  • Growth Hormone Deficiency in Children

Interventions

  • somapacitanDrug

    Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.

  • Norditropin®Drug

    Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height VelocityTime frame: Baseline (Week 0); Week 52

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Wuhan Children Hospital-Endocrine Genetics and Metabolism

    Wuhan, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Capital Center for Children's Health, Capital Medical University-Endocrinology

    Beijing, Beijing Municipality, China

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Xiamen University-Pediatric

    Xiamen, Fujian, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital, Sun Yat-Sen University-Pediatric

    Guangzhou, Guangdong, China

  • Henan Children's Hospital Zhengzhou Children's Hospital-Endocrine Genetics and Metabolism

    Zhengzhou, Henan, China

  • Henan Children's Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital, Tongji Medical College of HUST-Pediatric

    Wuhan, Hubei, China

  • Hunan Children's Hospital-Child Health Center

    Changsha, Hunan, China

  • Hunan Children's Hospital

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Shaoyang University-Pediatric

    Shaoyang, Hunan, China

  • Jiangxi Provincial Children's Hospital-Endocrine Genetics and Metabolism

    Nanchang, Jiangsu, China

  • Children's Hospital of Soochow University-Endocrine Genetics and Metabolism

    Suzhou, Jiangsu, China

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Wuxi Children's Hospital-Pediatric Endocrinology

    Wuxi, Jiangsu, China

  • Wuxi Children's Hospital

    Wuxi, Jiangsu, China

  • The First Hospital of Jiaxing-Pediatric

    Jiaxing, Jiangxi, China

  • The First Hospital of Jiaxing

    Jiaxing, Jiangxi, China

  • Pingxiang Maternal and Child Health Care Hospital-Child Health Care

    Pingxiang, Jiangxi, China

  • Pingxiang Maternal and Child Health Care Hospital

    Pingxiang, Jiangxi, China

  • The First Bethune Hospital of Jilin University-Pediatric

    Changchun, Jilin, China

  • The First Bethune hospital of Jilin University-Endocrinology

    Changchun, Julin, China

  • Shandong Provincial Hospital-Pediatric

    Jinan, Shandong, China

  • Women & Children's Health Care Hospital of Linyi-Endocrine Genetics and Metabolism

    Linyi, Shandong, China

  • Qingdao Women and Children's Hospital-Pediatric Endocrinology&Metabolism

    Qingdao, Shandong, China

  • Qingdao Women and Children's Hospital

    Qingdao, Shandong, China

  • Shanghai Children's Hospital

    Shanghai, Shanghai Municipality, China

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan, China

  • Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.